Drugs / WZTL-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04049513 | Oct 2019 → Jun 2024 overdue | follicular lymphoma, mantle cell lymphoma, primary mediastinal large B-cell lymphoma | Malaghan Institute of Medical Research | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06486051 | Jul 2024 → Jun 2026 overdue | large B-cell lymphoma, primary mediastinal large B-cell lymphoma | Malaghan Institute of Medical Research | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | BioOra Limited | Results Clinical Trial Results Support BioOra’s Automated CAR T-Cell Manufacturing for Next Phase bioora.com ↗
These results suggest that the treatment is not only effective but also exceptionally safe—key factors that could help this therapy become more widely accessible. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | BioOra Limited | BioOra signs definitive licence for WZTL-002 and announces NZ$30 million First Close of Series A2 bioora.com ↗ |
| 2023-12-12 | BioOra Limited | Clinical Trial Results Support BioOra’s Automated CAR T-Cell Manufacturing for Next Phase bioora.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WZTL-002 | “WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z).” NCT04049513 ↗ |
| Modality | Cell therapy | “WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells” NCT04049513 ↗ |
| Route | Intravenous | “WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion” NCT04049513 ↗ |
| Target | CD19 | “third-generation anti-CD19 chimeric antigen receptor T-cells” NCT04049513 ↗ |